Join Foundation Medicine in Chicago, Illinois, May 31-June 4, Booth #22031

Foundation Medicine is thrilled to be attending the 2024 ASCO® Annual Meeting in Chicago, Illinois, May 31 – June 4. We look forward to connecting with the oncology community and sharing how Foundation Medicine’s testing portfolio can inform treatment decisions for your advanced cancer patients.

We partner with both biopharma and clinical customers from biomarker discovery through commercialization with the goal of helping you miss not one opportunity for your patients.

Miss. Not. One.

Foundation Medicine is the global leader in approved companion diagnostic (CDx) indications.
FoundationOne®CDx and FoundationOne®Liquid CDx tests each detect:
- All 13 guideline-recommended somatic biomarkers in advanced breast cancer.^*1
- All 27 guideline-recommended biomarkers for advanced prostate cancer.^**2-5
- All 11 guideline-recommended genes in advanced non-small cell lung cancer (NSCLC).^***
Foundation Medicine’s FDA-approved portfolio offers:
- 6 CDx indications for breast cancer, the most of any comprehensive genomic profiling (CGP) company.¹
- 4 CDx indications for prostate cancer, the most of any company.^2-5
- 18+ CDx indications in NSCLC, the most of any company.
Foundation Medicine works with biopharma partners to accelerate translational research and commercialization of new therapies.
Clinical Trial and RUO assays enable next-generation biomarker discovery to support biopharma partners’ novel therapies.
- Identify biomarkers from common point mutations to complex gene-expression signatures including genomic signatures like HRD and complex alterations like MTAP loss.^†
- New biomarker discovery capabilities including whole-genome methylation sequencing and gene expression profiling.^†
Comprehensive NGS testing with existing CDx approvals can make biopharma partners’ path to approval faster.

Miss. Not. One.

Not all CGP tests are created equal, Foundation Medicine’s high-quality tests are different. Find more treatment options for your advanced cancer patients with our full portfolio of CGP tests. Miss. Not. One.

Please stop by Booth #22031 to meet our team or click here to schedule time during the annual meeting.

Meet with our team

Posters and Presentations

Exploiting circulating tumor DNA (ctDNA) to intensify the adjuvant or post-adjuvant treatment of stage III and high-risk stage II resected colon cancer patients: the ERASE-CRC project

First author

Chiara Cremolini

Collaborating Institution

University of Pisa, Italy

DO:

Colorectal

Abstract:

TPS3644 | Poster

Utility of circulating tumor DNA (ctDNA) to inform treatment of patients with metastatic breast cancer

First author:

Laura Linville

Collaborating Institution:

Johns Hopkins University School of Medicine, Baltimore, MD

DO:

Breast

Abstract:

1042 | Poster

Learn More

Prognostic value of baseline cell-free DNA (cfDNA) tumor fraction (TF) in metastatic hormone-sensitive prostate cancer (mHSPC)

First author:

Charles B. Nguyen

Collaborating Institution:

Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA

DO:

Prostate

Abstract:

5085 | Poster

Learn More

Utility of ctDNA burden as a prognostic biomarker for efficacy in TALAPRO-2: A phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate

First author:

Arun Azad

Collaborating Institution:

Peter MacCallum Cancer Centre, Department of Medical Oncology

DO:

Prostate

Abstract:

5020 | Poster

Learn More

BRCA1/2 Reversion Mutations in Advanced Prostate Cancer in the Absence of Prior PARP inhibitor (PARPi) Therapy

First author:

Douglas Lin

Institution:

Foundation Medicine, Inc.

DO:

Prostate

Abstract:

5056 | Poster

Learn More

Preliminary Results of the Lung Cancer Mutation Consortium - LCMC4 Evaluation of Actionable Drivers in EaRly Stage Lung Cancer (LEADER) Screening Trial

First author:

Jamie Chaft

Collaborating Institution:

Baylor College of Medicine

DO:

Lung

Abstract:

8068 | Poster

Learn More

Pathological complete response (pCR) association with a novel HRD signature (HRDsig) in triple-negative breast cancer (TNBC) patients receiving neoadjuvant therapy (Tx)

First author:

Tanya Gupta

Collaborating Institution:

Stanford University, Stanford, CA

DO:

Breast

Abstract:

591 | Poster

Genomic alterations (GA) in ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) patients (pts) with metastatic breast cancer (MBC): co-occurrence and prevalence along treatment course

First author:

Manali Bhave

Collaborating Institution:

Emory University, Atlanta, GA

DO:

Breast

Abstract:

1060 | Poster

Learn More

Characterization of diverse targetable ERBB2 alterations in 512,993 patients with solid tumors

First author:

Dazhi Liu

Collaborating Institution:

Memorial Sloan Kettering Cancer Center, New York, NY

DO:

Pan-tumor

Abstract:

3129

Learn More

Impact of HER2 Low Status on Genomic Signatures in Triple Negative Breast Cancer (TNBC)

First author:

Melissa Taylor

Institution:

Foundation Medicine, Inc.

DO:

Breast

Abstract:

1092 | Poster

Learn More

Nature and Distribution of Methyl thioadenosine phosphorylase (MTAP) Genomic Loss in Human Tumors

First author:

A Necchi

Collaborating Institution:

San Raffaele Hospital and Scientific Institute, Italy

DO:

Pan-tumor

Abstract:

3067 | Poster

Learn More

The Increasing Frequency of Inactivating STK11 Mutations in Lung Adenocarcinomas (LA) over a Ten-Year Period likely Indicates the Development of Acquired Resistance to Immune Checkpoint Inhibitor (ICPI) Based Treatments

First author:

Deevyashali Parekh

Institution:

Foundation Medicine, Inc.

DO:

Lung

Abstract:

8032 | Poster

Molecular Profiling across Histologies in Lung Cancer: Time to change WHO nomenclature?

First author:

Alessandro Russo

Collaborating Institution:

Center for Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA

DO:

Lung

Abstract:

8532 | Poster

Learn More

FGFR3 Mutated (FGFR3mut+) Urothelial Carcinoma of Bladder (UCB) and Upper Tract (UTUC) Including Ureter (UUC) and Renal Pelvis (RPUC): a Comparative Genomic Profiling Study

First author:

M Basin

Collaborating Institution:

Foundation Medicine, Inc.

DO:

Bladder

Abstract:

4588 | Poster

Learn More

On the Right TRACK: Operationalizing a National, Patient-Centric Fully Remote Precision Trial Offering Comprehensive Genomic Profiling and a Molecular Tumor Board for Rare Cancers

First author:

Jim Palma

Collaborating Institution:

TargetCancer Foundation, Cambridge, Massachusetts, USA

DO:

Multi-tumor

Abstract

3127 | Poster

Learn More

Contrasting Comprehensive Genomic Profiles (CGP) of Adenocarcinomas of the Appendix (AAC) in Young verses Older patients

First author:

Myera Shahnawaz

Collaborating Institution:

Foundation Medicine, Inc.

DO:

Appendix

Abstract:

3626 | Poster

Learn More

Intimal Sarcomas (ISarc) of the Cardiac Chambers (CC) of the Heart and Great Vessels (GV): A Comprehensive Genomic Profiling (CGP) Study

First author:

Maroun Bou Zerdan

Collaborating Institution:

Foundation Medicine, Inc.

DO:

Heart

Abstract:

11575 | Poster

Learn More

Impact of alterations in Tumor Suppressor Genes (TSG-alt) on Survival Outcomes in patients (pts) with de novo metastatic castration-sensitive prostate cancer (dn-mCSPC) receiving intensified androgen deprivation therapy (ADTi).

First author:

Arshit Narang

Institution:

Foundation Medicine, Inc.

DO:

Prostate

Abstract:

5091 | Poster

Learn More

Outcomes and clinical, molecular, and immune profiling of head and neck squamous cell carcinoma (HNSCC) brain metastases (BM)

First author:

Michael Dennis

Collaborating Institution:

Dana-Farber Cancer Institute

DO:

Head and neck

Abstract:

6036 | Poster

New soft tissue sarcoma (STS) transcriptomic clusters unveil STS subsets with unique biological characteristics and refine the accuracy of overall survival (OS) prediction

First author:

Miguel Esperanca-Martins

Collaborating Institution:

Medical Oncology Department, Centro Hospitalar Universitario Lisboa Norte, Lisboa, Portugal

DO:

Sarcoma

Abstract:

11545 | Poster

Learn More

Genetic ancestry-associated differences in genomic profiling and treatment patterns in pancreatic ductal adenocarcinoma (PDAC)

First author:

Jacquelyne Gaddy

Collaborating Institution:

Yale Cancer Center, New Haven, CT, USA

DO:

Pancreatic

Abstract:

4138 | Poster

Learn More

The Landscape of Genomic Biomarkers, Ancestry, and Real-World Outcomes in ERBB2 Amplified Endometrial Carcinoma (EC)

First author:

Thomas Herzog

Collaborating Institution:

Foundation Medicine, Inc.

DO:

Endometrial

Abstract:

5614 | Poster

FoundationOne®CDx and FoundationOne®Liquid CDx are qualitative next-generation sequencing based in vitro diagnostic tests for advanced cancer patients with solid tumors and are for prescription use only. FoundationOne CDx utilizes FFPE tissue and analyzes 324 genes as well as genomic signatures. FoundationOne Liquid CDx analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes. The tests are companion diagnostics to identify patients who may benefit from treatment with specific therapies in accordance with the therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the tests does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy for testing with FoundationOne CDx when archival tissue is not available which may pose a risk. Patients being considered for eligibility for therapy based on detection of NTRK1/2/3 and ROS1 fusions should only be tested if tissue is unavailable. Patients who are tested with FoundationOne Liquid CDx and are negative for other companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com and www.F1LCDxLabel.com.

*Based on genomic testing guidelines in advanced breast cancer. Does not include germline or IHC testing.

**Based on somatic testing guidelines in advanced prostate cancer, including 19 HRR genes, MSI/MSI-H, plus 7 clinically relevant biomarkers (TMB, MSH2, MSH6, PMS2, PTEN, RB1, TP53).

*** Data on File, Foundation Medicine, Inc., October 2023.

†Research use only.

1. Data on File, Foundation Medicine, Inc., 2024

2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V4.2023. © 2023 National Comprehensive Cancer Network, Inc. All rights reserved. Accessed February 12, 2024. To view the most recent and complete version of the guidelines, go online to NCCN.org.

3. FoundationOne Liquid CDx Technical Specifications (Gene List). https://www.foundationmedicine.com/sites/default/files/media/documents/2023-10/F1LCDx_Technical_Specs_072021-2.pdf. Accessed February 13, 2024.

4. FoundationOne CDx Technical Specifications (Gene List). https://www.foundationmedicine.com/sites/default/files/media/documents/2024-01/F1CDx%20Technical%20Specifications%20SPEC-01197.pdf. Accessed February 13, 2024.

5. Data on File, Foundation Medicine, Inc., August 2023.